CPC C07K 16/2803 (2013.01) [A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); C07K 16/2896 (2013.01); A61K 38/1816 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); Y02A 50/30 (2018.01)] | 18 Claims |
1. A method for treating cancer in a human subject, the method comprising:
(a) administering a sub-therapeutic dose of from 0.1 mg/kg to 10 mg/kg of an anti-CD47 antibody that blocks the interaction between CD47 and SIRPα, wherein the sub-therapeutic dose is sufficient to increase production of reticulocytes; and
(b) administering a therapeutically effective dose of an anti-CD47 antibody that blocks the interaction between CD47 and SIRPα; wherein step (b) is performed in a range of from 5 to 9 days after beginning step (a), thereby treating the cancer.
|